ES2129551T3 - Vacuna contra la enfermedad de lyme. - Google Patents

Vacuna contra la enfermedad de lyme.

Info

Publication number
ES2129551T3
ES2129551T3 ES94112143T ES94112143T ES2129551T3 ES 2129551 T3 ES2129551 T3 ES 2129551T3 ES 94112143 T ES94112143 T ES 94112143T ES 94112143 T ES94112143 T ES 94112143T ES 2129551 T3 ES2129551 T3 ES 2129551T3
Authority
ES
Spain
Prior art keywords
burgdorferi
inventory
book
ecacc
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94112143T
Other languages
English (en)
Inventor
Markus M Dr Simon
Ulrich E Schaible
Klaus Prof Dr Eichmann
Michael Dr Kramer
Wallich Dr Reinhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2129551(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforschungszentrum DKFZ, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2129551T3 publication Critical patent/ES2129551T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UNA VACUNA PASIVA CONTRA LA ENFERMEDAD DE LYME, QUE CONTIENE UNO O MULTIPLES ANTICUERPOS MONOCRONALES ESPECIFICOS DEL ANTIGENO 31 KD (OSPA) Y/O EN ANTIGENO 34 KD (OSPB) DEL B. BURGDORFERI Y EVITA EN ANIMALES DE ENSAYO INMUNODEFICIENTES, QUE HAN SIDO INFECTADOS CON ORGANISMOS PATOGENOS CON CAPACIDAD DE VIDA DEL B. BURGDORFERI, LA FORMACION DE ARTRITIS, PANCARDITIS Y HEPATITIS. LA INVENCION SE REFIERE TAMBIEN ADEMAS A UN PROCEDIMIENTO PARA LA OBTENCION DE LA VACUNA DE ACUERDO CON LA INVENCION, LA HYBRIDOMA-ZELLINIEN ECACC 89 09 1302, ECACC 90050405, ECACC 90050406 Y ECACC 90050407, QUE SEGREGAN ANTICUERPOS DE ACUERDO CON LA INVENCION Y EL B. BURGDORFERI PATOGENO DEL TRONCO ZS7 (DSM 5527). EVENTUALMENTE EL OBJETIVO DE LA INVENCION ES UN ANTIGENO A PARTIR DEL B. BURGDORFERI, QUE REACCIONA DE FORMA INMUNE CON UN ANTICUERPO DE ACUERDO CON LA INVENCION, UN PROCEDIMIENTO PARA LA OBTENCION DEL ANTIGENO DE ACUERDO CON LA INVENCION ASI COMO VACUNAS ACTIVAS CONTRA LA ENFERMEDAD DE LIME, QUE CONTIENEN ANTIGENOS DE ACUERDO CON LA INVENCION COMO COMPONENTE ESENCIAL. LA INVENCION SE REFIERE FINALMENTE A UN PROCEDIMIENTO PARA EL AISLAMIENTO Y RECULTIVO DE ORGANISMOS PATOGENOS B. BURGDORFERI A PARTIR DE ANIMALES DE ENSAYO INMUNODEFICIENTES.
ES94112143T 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme. Expired - Lifetime ES2129551T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit

Publications (1)

Publication Number Publication Date
ES2129551T3 true ES2129551T3 (es) 1999-06-16

Family

ID=25885304

Family Applications (4)

Application Number Title Priority Date Filing Date
ES94112145T Expired - Lifetime ES2141182T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES94112143T Expired - Lifetime ES2129551T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES94112144T Expired - Lifetime ES2145077T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES90117943T Expired - Lifetime ES2082812T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94112145T Expired - Lifetime ES2141182T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES94112144T Expired - Lifetime ES2145077T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES90117943T Expired - Lifetime ES2082812T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Country Status (23)

Country Link
US (6) US5178859A (es)
EP (5) EP0418827B1 (es)
JP (3) JP3205932B2 (es)
KR (2) KR100205462B1 (es)
AT (4) ATE186646T1 (es)
AU (1) AU651560B2 (es)
CA (1) CA2025597C (es)
CZ (2) CZ284616B6 (es)
DE (5) DE4015911A1 (es)
DK (4) DK0633028T3 (es)
ES (4) ES2141182T3 (es)
FI (1) FI102248B (es)
GR (3) GR3018995T3 (es)
HR (1) HRP940545B1 (es)
HU (2) HU212716B (es)
IE (1) IE903377A1 (es)
NO (2) NO311767B1 (es)
NZ (1) NZ235260A (es)
PL (2) PL169804B1 (es)
PT (1) PT95349B (es)
SI (1) SI9011773B (es)
SK (3) SK283088B6 (es)
YU (2) YU48250B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
CA2084413A1 (en) 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
EP1589109B1 (en) 1996-02-21 2017-04-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic borrelia
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
EP1100922B1 (en) 1998-07-31 2008-02-20 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
WO2000056298A2 (en) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Treatment of lyme disease with polysulfated glycosaminoglycan formulations
AU4800500A (en) * 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
ATE381575T1 (de) 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
WO2004058181A2 (en) 2002-12-20 2004-07-15 Board Of Regents, The University Of Texas System Vmp-like sequences of pathogenic borrelia species and strains
UA99719C2 (ru) 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2501719B1 (en) * 2009-11-17 2015-11-04 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DK0506868T4 (da) * 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0642574B1 (en) * 1991-08-27 1998-12-09 Novo Nordisk A/S Detergent compositions
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター

Also Published As

Publication number Publication date
DK0633028T3 (da) 2000-04-10
DE4015911A1 (de) 1991-03-28
JP2001204467A (ja) 2001-07-31
ATE191499T1 (de) 2000-04-15
DE59010888D1 (de) 1999-12-23
ATE131732T1 (de) 1996-01-15
ES2141182T3 (es) 2000-03-16
GR3018995T3 (en) 1996-05-31
EP0633313A1 (de) 1995-01-11
JP2001069969A (ja) 2001-03-21
EP0633313B1 (de) 2000-04-05
HRP940545B1 (en) 2000-06-30
SK456090A3 (en) 1999-11-08
SK283089B6 (sk) 2003-02-04
ES2082812T3 (es) 1996-04-01
JP3328644B2 (ja) 2002-09-30
IE990173A1 (en) 2000-11-01
HU212716B (en) 1996-10-28
FI904597A0 (fi) 1990-09-18
HU905816D0 (en) 1991-03-28
HK1013620A1 (en) 1999-09-03
CA2025597A1 (en) 1991-03-20
HRP940545A2 (en) 1997-04-30
SK151198A3 (en) 1999-04-13
US5686267A (en) 1997-11-11
CZ284538B6 (cs) 1998-12-16
EP0861664A2 (de) 1998-09-02
DK0643974T3 (da) 1999-09-06
SK151098A3 (en) 1999-04-13
YU48250B (sh) 1997-09-30
PL170229B1 (pl) 1996-11-29
HU211228A9 (en) 1995-11-28
ATE186646T1 (de) 1999-12-15
EP0633028B1 (de) 1999-11-17
EP0643974B1 (de) 1999-01-13
US6613331B1 (en) 2003-09-02
DE59010903D1 (de) 2000-05-11
PT95349B (pt) 1997-06-30
YU177390A (sh) 1993-05-28
US5856447A (en) 1999-01-05
GR3032010T3 (en) 2000-03-31
DE59009978D1 (de) 1996-02-01
EP0633028A1 (de) 1995-01-11
NO904062L (no) 1991-03-20
US5780030A (en) 1998-07-14
CZ284616B6 (cs) 1999-01-13
CZ456090A3 (cs) 1998-08-12
SK280285B6 (sk) 1999-11-08
EP0861664A3 (de) 1999-02-24
YU9097A (sh) 1999-06-15
JPH03209400A (ja) 1991-09-12
HK1002405A1 (en) 1998-08-21
DK0418827T3 (da) 1996-05-06
AU6244490A (en) 1991-03-28
ES2145077T3 (es) 2000-07-01
EP0418827A1 (de) 1991-03-27
HUT59613A (en) 1992-06-29
JP3205932B2 (ja) 2001-09-04
IE903377A1 (en) 1991-04-10
YU49370B (sh) 2005-09-19
SI9011773A (sl) 1998-04-30
SK283088B6 (sk) 2003-02-04
NO904062D0 (no) 1990-09-18
FI102248B1 (fi) 1998-11-13
NO311767B1 (no) 2002-01-21
NO20014624D0 (no) 2001-09-24
US5178859A (en) 1993-01-12
FI102248B (fi) 1998-11-13
NO315905B1 (no) 2003-11-10
NZ235260A (en) 1993-04-28
DK0633313T3 (da) 2000-07-24
AU651560B2 (en) 1994-07-28
EP0418827B1 (de) 1995-12-20
GR3033675T3 (en) 2000-10-31
CA2025597C (en) 2004-02-03
CZ97095A3 (en) 1995-09-13
KR100202128B1 (en) 1999-06-15
PT95349A (pt) 1991-05-22
JP3418171B2 (ja) 2003-06-16
DE59010863D1 (de) 1999-02-25
US5434077A (en) 1995-07-18
SI9011773B (en) 2001-12-31
ATE175576T1 (de) 1999-01-15
NO20014624L (no) 1991-03-20
KR100205462B1 (ko) 1999-07-01
KR910005889A (ko) 1991-04-27
PL169804B1 (pl) 1996-09-30
EP0643974A1 (de) 1995-03-22

Similar Documents

Publication Publication Date Title
ES2129551T3 (es) Vacuna contra la enfermedad de lyme.
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
PE20231748A1 (es) ANTICUERPOS ANTI-N3pGlu BETA AMILOIDE Y USOS DE ESTOS
DE68926300D1 (de) Neues virus, verantwortlich für die infektiöse erkrankung der bursa fabricius
CO6190537A2 (es) Vacuna para la enfermedad de lyme canina
ES2059670T3 (es) Una nueva familia de anticuerpos modificados, de alta afinidad, para el tratamiento del cancer.
AR087749A1 (es) Anticuerpos anti-xcr1 humano
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
BR0209562A (pt) Molécula de conjugado imunogênico, composição farmacêutica, método para preparar uma molécula de conjugado de polipeptìdeo-ácido hialurÈnico de baixo peso molecular, anticorpo purificado, métodos para eliciar uma resposta anticorpo em um mamìfero, e para inibir infecção estreptocócica em um mamìfero e a progressão de infecção em um mamìfero por bactérias contendo ha, e, kit de imunoensaio diagnóstico
Holt et al. Protective effect of sera raised against different fractions of Streptococcus suis type 2
CN104059134B (zh) 败血性巴氏杆菌毒素重组蛋白及其应用
Madigan Lyme disease (Lyme borreliosis) in horses
CR20230245A (es) Moléculas de unión a gucy2c y sus usos
Seed Trypanosoma gambiense and T. equiperdum: Characterization of variant specific antigens
ATE151994T1 (de) Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten
CA2597701A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype
Cevenini et al. Complement-mediated in vitro bactericidal activity of monoclonal antibodies reactive with outer-surface-protein OspB of Borrelia burgdorferi
Silkina et al. New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A
Talmage Origins of the cell selection theories of antibody formation
ATE145236T1 (de) Für die infektiöse erkrankung der bursa fabricius verantwortlicher virus
Waghela et al. Antigenic analysis of Anaplasma marginale grown in bovine erythrocytes co-cultured with bovine endothelial cells
Mendes et al. Epitope mapping of the antigenic protein TsNTxP from Tityus serrulatus scorpion venom using mouse, rabbit and sheep antibodies
Banks et al. Serotyping of Chlamydia: antibodies to lymphogranuloma venereum strains compared by microimmunofluorescence and neutralization tests

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643974

Country of ref document: ES